Non-Hodgkin'S Lymphoma in Northern Sweden Prognostic Factors and Response to Treatment

Abstract

A total of 352 cases of non-Hodgkin's lymphoma reported to the Cancer Registry of Northern Sweden during 1978-1982 were retrospectively analysed. After morphologic review, 327 cases classifiable as low (n = 162) or high-grade (n = 165) according to the Kiel classification remained for further study. The purpose of the study was to evaluate the interrelations between some variables and their bearing on prognosis in an almost unselected clinical material. Age, morphological grade of malignancy, clinical stage, systemic symptoms, bulk of disease and serum lactate dehydrogenase (LDH) level turned out to be associated with the clinical outcome in terms of response to treatment, disease-free survival and survival. In the heterogenous group of low-grade lymphoma, six pretreatment characteristics were negatively associated with survival in a univariate analysis, namely; stage II-IV, systemic symptoms, bone marrow infiltration, two or more extranodal sites, elevated LDH and age above 65 years. In high-grade lymphoma, stage II-IV, bone marrow infiltration and elevated LDH predicted a worse prognosis in a multivariate analysis. The impact of the number of these prognostic factors on survival in high-grade lymphoma was demonstrated.

High-Grade Non-Hodgkin's Lymphoma Stage I: A retrospective study of treatment, outcome and prognostic factors in 213 patients

“…As a result of the salvage treatment no significant difference in 5-year survival between the different treatment groups was observed. The prognostic factors shown in our material agree on the whole with other reports with the exception that no prognostic significance of tumor size was found in our study (8,9,17,(21)(22)(23)(24). One reason for this discrepancy may be the fact that most patients in our material with large tumor volume were given more intense treatment, which may have improved the treatment results in this group.…”

“…Our knowledge concerning adverse prognostic pretreatment factors is improving which should be considered when the treatment of the patient is decided (9,17,(21)(22)(23)(24). We now report the results of a retrospective study comprising all consecutive patients with high-grade stage I non-Hodgkin's lymphoma treated at three departments of oncology in Sweden during the period [1985][1986][1987][1988][1989][1990].…”

Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin’s lymphoma

“…An inverse correlation was detected between IPI scores, and response rates. In the literature, higher IPI score, advanced stage, aggressive lymphoma subgroup according to WHO classification were observed to be poor prognostic parameters [31,35].…”

Different alterations in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin's and non‐Hodgkin's lymphomas

“…In patients with malignant lymphomas among biochemical parameters lactate dehydrogenase (LDH) represents a very valuable enzyme, and its serum level has been considered as very important in the evaluation of disease extension in non-Hodgkin's lymphomas (NHL) (1) and Hodgkin's disease (HD) (2). Considering that elevation of serum LDH level correlates with bulky tumor mass (3,4), it represents an important independent prognostic factor for patients with lymphomas (5,6). Furthermore, evaluation of lactate dehydrogenase, owing to its very well de®ned structural and kinetic characteristics, gives valuable data concerning cellular metabolic status.…”